A recent extensive cohort study on ALK aberration in RMS17 revealed that approximately 90% of ARMS patients and 50% of ERMS patients exhibited ALK copy number gains, whereas only 4% of RMS patients showed true amplification of ALK. In our study, ALK amplification was not observed, although ALK was overexpressed. Here, ALK is linked to alveolar rhabdomyosarcoma.